UniQure Huntington's therapy does not reach statistical significance in trial
UniQure said its Huntington's treatment slowed disease progression by 44% but did not reach statistical significance in an ongoing early-to-mid-stage trial.
Sept. 29 (Reuters) — UniQure said on Tuesday its Huntington's treatment slowed disease progression by 44%, but the result did not reach statistical significance in an ongoing early-to-mid-stage trial. -listed shares were down 63% in premarket trading.